PACT Pharma is described as a next‑gen T cell therapy player focused on neoantigen TCR approaches. The company is advancing neoantigen-specific T cell receptor work and is investing in manufacturing capabilities. It has secured $75 million to support its neoantigen TCR programs and manufacturing efforts. The article notes the company has brought in a new president and a new chief technical officer. No revenue or user metrics were reported in the article. Further operational or financial details were not provided.

Total raised

$75M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2020